Over
90+ Schizophrenia pipeline therapies are under different stages of development and their expected approval in the Schizophrenia market shall uplift the market revenue significantly.
Out of emerging therapies,
AVP-786 is in Phase II/III stage of trials. Similarly,
MK-8189 is undergoing Phase II developmental phase for Schizophrenia.
Schizophrenia pipeline therapies in the early stages of development include
CAD-9303, and
In December 2020, FDA assigns PDUFA action date of (01/06/2021) for
ALKS 3831 for Schizophrenia and Bipolar disorders.
In June 2020, Neurocrine Biosciences and Takeda entered into a strategic collaboration agreement to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical-stage assets for schizophrenia, treatment-resistant depression, and anhedonia.